Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03923920 · ClinicalTrials.gov registry record

Screening for Systemic Amyloidosis Via the Ligamentum Flavum

A clinical trial of Amyloidosis and Spinal Stenosis, sponsored by The Cleveland Clinic.

Completed
Registry status
200
Enrollment target
1
Study location

NCT03923920 is a study of Amyloidosis and Spinal Stenosis that has completed, run by The Cleveland Clinic. The registered enrollment target is 200 participants, below the 1,122-participant average among 28 other Amyloidosis trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03923920, a study of Amyloidosis and Spinal Stenosis, has completed, sponsored by The Cleveland Clinic.

COMPLETED
Registry status
200 participants
Enrollment target
1
Study location

Study Summary

The investigators will prospectively evaluate for the presence of amyloid deposits in ligamentum flavum (yellow ligament) tissue samples obtained from patients undergoing spinal stenosis surgery. Patients who have tissue that stains positive for amyloid will be referred to an amyloidosis specialist.

Interventions

  • PROCEDURE Biopsy

Study Locations (1)

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2019-05-01
Est. Completion 2021-12-02

Sponsor

The Cleveland Clinic

688 total trials

What the Registry Record Tells You About NCT03923920

The ClinicalTrials.gov registry entry for NCT03923920 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,122-participant average among 28 other Amyloidosis trials with a reported enrollment target (82% lower). The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which Biopsy is the first listed.

NCT03923920 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT03923920 about?

NCT03923920 is a clinical study titled "Screening for Systemic Amyloidosis Via the Ligamentum Flavum". The investigators will prospectively evaluate for the presence of amyloid deposits in ligamentum flavum (yellow ligament) tissue samples obtained from patients undergoing spinal stenosis surgery. Patients who have tissue that stains positive for amyloid will be referred to an amyloidosis specialist.

What is the current status of trial NCT03923920?

This trial is currently completed. The enrollment target is 200 participants. The study started on 2019-05-01. Estimated completion is 2021-12-02.

What conditions does trial NCT03923920 study?

This clinical trial studies the following conditions: Amyloidosis, Spinal Stenosis, Transthyretin Amyloidosis, Amyloid, Primary Amyloidosis of Light Chain Type.

What interventions are being tested in trial NCT03923920?

The interventions under investigation include: Biopsy (PROCEDURE).

Who is sponsoring clinical trial NCT03923920?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03923920 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Amyloidosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.